Trial Outcomes & Findings for Study of GSK3511294 in Healthy Chinese Participants (NCT NCT05140200)

Last Updated: 2026-05-26

Results Overview

Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Infinity). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

20 participants

Primary outcome timeframe

Day 1 (Pre-dose, 2h, and 8h Post-dose), Day 2, Day 3, Day 5, Day 8, Day 15, Day 29, Day 57, Day 85, Day 127, Day 169, and Day 183

Results posted on

2026-05-26

Participant Flow

A total of 20 participants were enrolled and randomized in 1:1 ratio in each arm to receive either depemokimab 100 milligrams (mg) or 300 mg.

Participant milestones

Participant milestones
Measure	Depemokimab 100mg Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Overall Study STARTED	10	10
Overall Study COMPLETED	10	9
Overall Study NOT COMPLETED	0	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Depemokimab 100mg Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Overall Study Lost to Follow-up	0	1

Baseline Characteristics

Study of GSK3511294 in Healthy Chinese Participants

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.	Total n=20 Participants Total of all reporting groups
Age, Continuous	30.0 Years STANDARD_DEVIATION 6.23 • n=20 Participants	29.4 Years STANDARD_DEVIATION 6.92 • n=32 Participants	29.7 Years STANDARD_DEVIATION 6.41 • n=64 Participants
Sex: Female, Male Female	0 Participants n=20 Participants	0 Participants n=32 Participants	0 Participants n=64 Participants
Sex: Female, Male Male	10 Participants n=20 Participants	10 Participants n=32 Participants	20 Participants n=64 Participants
Race/Ethnicity, Customized Asian - East Asian Heritage	10 Participants n=20 Participants	10 Participants n=32 Participants	20 Participants n=64 Participants

PRIMARY outcome

Timeframe: Day 1 (Pre-dose, 2h, and 8h Post-dose), Day 2, Day 3, Day 5, Day 8, Day 15, Day 29, Day 57, Day 85, Day 127, Day 169, and Day 183

Population: The analysis was performed on pharmacokinetic set which included all participants who received at least one dose of study intervention and for whom at least one evaluable pharmacokinetic sample was obtained and analysed. Participants were analyzed according to the intervention they actually received. Only those participants with data available at the specified time points were analyzed.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=9 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero (Pre-Dose) Extrapolated to Infinite Time (AUC[0-Infinity]) of Depemokimab	1685.946 day*micrograms per millilitres Interval 1540.9579 to 1844.5771	5224.107 day*micrograms per millilitres Interval 4713.29 to 5790.2848

PRIMARY outcome

Timeframe: Day 1 (Pre-dose, 2h, and 8h Post-dose), Day 2, Day 3, Day 5, Day 8, Day 15, Day 29, Day 57, Day 85, Day 127, Day 169, and Day 183

Blood samples were collected from participants at indicated time points and analyzed for AUC(0-T). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=9 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
AUC From Time 0 (Pre-Dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC[0-T]) of Depemokimab	1472.963 day*micrograms per millilitres Interval 1346.2052 to 1611.6562	4604.879 day*micrograms per millilitres Interval 4133.2379 to 5130.3394

PRIMARY outcome

Timeframe: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, and 29

Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 4). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 4 post-dose correlates to Day 1 plus 28 days, that is, Day 29.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
AUC From Time 0 (Pre-dose) to Week 4 (AUC[0-Week 4]) of Depemokimab	414.467 day*micrograms per millilitres Interval 367.9103 to 466.9157	1357.843 day*micrograms per millilitres Interval 1207.8494 to 1526.4621

PRIMARY outcome

Timeframe: Pre-dose (Day 1); 2 h, 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, and 85

Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 12). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, that is, Day 85.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=9 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
AUC From Time 0 (Pre-dose) To Week 12 (AUC[0-Week 12]) Of Depemokimab	1027.083 day*micrograms per millilitres Interval 933.7879 to 1129.699	3255.132 day*micrograms per millilitres Interval 2902.9404 to 3650.0522

PRIMARY outcome

Timeframe: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 26). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=9 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
AUC From Time 0 (Pre-dose) To Week 26 [AUC(0-Week 26)] of Depemokimab	1472.912 day*micrograms per millilitres Interval 1346.2052 to 1611.5454	4605.772 day*micrograms per millilitres Interval 4134.0654 to 5131.3018

PRIMARY outcome

Timeframe: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

Blood samples were collected from participants at indicated time points and analyzed for percentage of AUC(0-Infinity) obtained by extrapolation. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=9 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Percentage Of AUC(0-Infinity) Obtained by Extrapolation (%AUCex) of Depemokimab	12.381 Percentage of AUCex Interval 10.7508 to 14.2591	11.611 Percentage of AUCex Interval 9.9214 to 13.5888

PRIMARY outcome

Timeframe: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

Blood samples were collected from participants at indicated time points and analyzed for Cmax. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Maximum Observed Plasma Concentration (Cmax) of Depemokimab	16.82 micrograms per milliliters (mcg/mL) Interval 14.782 to 19.144	55.04 micrograms per milliliters (mcg/mL) Interval 48.183 to 62.867

PRIMARY outcome

Timeframe: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

Blood samples were collected from participants at indicated time points and analyzed for Tmax. Pharmacokinetic parameters were calculated by standard non compartmental analysis. Tmax was determined directly from the plasma concentration-time data. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Time of Occurrence of Cmax (Tmax) Of Depemokimab	13.960 Days Interval 3.98 to 27.95	13.980 Days Interval 4.0 to 27.98

PRIMARY outcome

Timeframe: Pre-dose (day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

Blood samples were collected from participants at indicated time points and analyzed for Tlast. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=9 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Time To Last Quantifiable Concentration (Tlast) of Depemokimab	181.980 Days Interval 181.97 to 182.19	181.980 Days Interval 180.96 to 182.06

PRIMARY outcome

Timeframe: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

Blood samples were collected from participants at indicated time points and analyzed for Apparent Clearance. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=9 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Apparent Clearance (CL/F) of Depemokimab	0.0593 Liters per day Interval 0.0542 to 0.0649	0.0574 Liters per day Interval 0.0518 to 0.0636

PRIMARY outcome

Timeframe: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

Blood samples were collected from participants at indicated time points and analyzed for apparent volume of distribution. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=9 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Apparent Volume of Distribution (Vz/F) of Depemokimab	5.033 Litres Interval 4.5599 to 5.5554	4.827 Litres Interval 4.2489 to 5.483

PRIMARY outcome

Timeframe: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

Blood samples were collected from participants at indicated time points and analyzed for Terminal elimination rate constant. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=9 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Terminal Elimination Rate Constant (Lambda Z) of Depemokimab	0.0118 Per Day Interval 0.0111 to 0.0125	0.0119 Per Day Interval 0.0112 to 0.0127

PRIMARY outcome

Timeframe: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

Blood samples were collected from participants at indicated time points and analyzed for Terminal phase half-life. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=9 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Terminal Phase Half-Life (T1/2) of Depemokimab	58.827 Days Interval 55.5367 to 62.3132	58.246 Days Interval 54.7008 to 62.0215

SECONDARY outcome

Timeframe: From the start of the study intervention (Day 1) up to Day 211 (End of follow-up)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or is considered or defined as an important medical event.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Number of Participants With Adverse Events (AE) And Serious Adverse Events (SAEs) Adverse Events	10 Participants	10 Participants
Number of Participants With Adverse Events (AE) And Serious Adverse Events (SAEs) Serious Adverse Events	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26

Population: The analysis was performed on the Safety Set that included all participants who received at least one dose of study intervention. Participants were analysed according to the intervention they actually received. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points.

Blood samples were collected for the assessment of hematology parameters including (WBC) count with differential that is, Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Day 2	-0.000 10^9 cells/L Standard Deviation 0.0125	-0.007 10^9 cells/L Standard Deviation 0.0082
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Day 3	-0.006 10^9 cells/L Standard Deviation 0.0126	-0.002 10^9 cells/L Standard Deviation 0.0123
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Day 5	-0.005 10^9 cells/L Standard Deviation 0.0127	-0.002 10^9 cells/L Standard Deviation 0.0132
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Week 1	-0.007 10^9 cells/L Standard Deviation 0.0082	-0.009 10^9 cells/L Standard Deviation 0.0074
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Week 2	-0.006 10^9 cells/L Standard Deviation 0.0107	-0.009 10^9 cells/L Standard Deviation 0.0099
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Week 4	-0.010 10^9 cells/L Standard Deviation 0.0156	-0.009 10^9 cells/L Standard Deviation 0.0129
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Week 8	-0.001 10^9 cells/L Standard Deviation 0.0120	-0.011 10^9 cells/L Standard Deviation 0.0129
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Week 12	-0.010 10^9 cells/L Standard Deviation 0.0105	-0.014 10^9 cells/L Standard Deviation 0.0133
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Week 18	-0.009 10^9 cells/L Standard Deviation 0.0099	-0.009 10^9 cells/L Standard Deviation 0.0105
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Week 24	-0.005 10^9 cells/L Standard Deviation 0.0135	-0.016 10^9 cells/L Standard Deviation 0.0174
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Basophils, Week 26	-0.004 10^9 cells/L Standard Deviation 0.0135	-0.007 10^9 cells/L Standard Deviation 0.0100
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Day 2	-0.090 10^9 cells/L Standard Deviation 0.0720	-0.046 10^9 cells/L Standard Deviation 0.0401
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Day 3	-0.101 10^9 cells/L Standard Deviation 0.0824	-0.049 10^9 cells/L Standard Deviation 0.0463
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Day 5	-0.114 10^9 cells/L Standard Deviation 0.0875	-0.059 10^9 cells/L Standard Deviation 0.0404
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Week 1	-0.117 10^9 cells/L Standard Deviation 0.0858	-0.060 10^9 cells/L Standard Deviation 0.0429
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Week 2	-0.122 10^9 cells/L Standard Deviation 0.0889	-0.055 10^9 cells/L Standard Deviation 0.0414
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Week 4	-0.128 10^9 cells/L Standard Deviation 0.0986	-0.063 10^9 cells/L Standard Deviation 0.0499
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Week 8	-0.129 10^9 cells/L Standard Deviation 0.1092	-0.068 10^9 cells/L Standard Deviation 0.0432
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Week 12	-0.132 10^9 cells/L Standard Deviation 0.1017	-0.068 10^9 cells/L Standard Deviation 0.0435
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Week 18	-0.123 10^9 cells/L Standard Deviation 0.0943	-0.064 10^9 cells/L Standard Deviation 0.0522
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Week 24	-0.126 10^9 cells/L Standard Deviation 0.0982	-0.077 10^9 cells/L Standard Deviation 0.0480
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Eosinophils, Week 26	-0.122 10^9 cells/L Standard Deviation 0.0919	-0.069 10^9 cells/L Standard Deviation 0.0506
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Day 2	-0.23 10^9 cells/L Standard Deviation 0.337	-0.11 10^9 cells/L Standard Deviation 0.088
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Day 3	-0.32 10^9 cells/L Standard Deviation 0.385	-0.16 10^9 cells/L Standard Deviation 0.276
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Day 5	-0.14 10^9 cells/L Standard Deviation 0.337	-0.18 10^9 cells/L Standard Deviation 0.204
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Week 1	-0.20 10^9 cells/L Standard Deviation 0.327	-0.23 10^9 cells/L Standard Deviation 0.177
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Week 2	-0.03 10^9 cells/L Standard Deviation 0.440	0.01 10^9 cells/L Standard Deviation 0.191
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Week 4	0.12 10^9 cells/L Standard Deviation 0.505	-0.09 10^9 cells/L Standard Deviation 0.260
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Week 8	0.16 10^9 cells/L Standard Deviation 0.320	0.03 10^9 cells/L Standard Deviation 0.353
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Week 12	-0.21 10^9 cells/L Standard Deviation 0.331	-0.04 10^9 cells/L Standard Deviation 0.381
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Week 18	-0.11 10^9 cells/L Standard Deviation 0.384	-0.12 10^9 cells/L Standard Deviation 0.291
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Week 24	-0.20 10^9 cells/L Standard Deviation 0.422	-0.20 10^9 cells/L Standard Deviation 0.418
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Lymphocytes, Week 26	-0.21 10^9 cells/L Standard Deviation 0.477	-0.18 10^9 cells/L Standard Deviation 0.427
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Day 2	-0.05 10^9 cells/L Standard Deviation 0.085	0.01 10^9 cells/L Standard Deviation 0.057
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Day 3	-0.06 10^9 cells/L Standard Deviation 0.084	0.04 10^9 cells/L Standard Deviation 0.052
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Day 5	0.01 10^9 cells/L Standard Deviation 0.088	0.05 10^9 cells/L Standard Deviation 0.053
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Week 1	-0.05 10^9 cells/L Standard Deviation 0.097	0.04 10^9 cells/L Standard Deviation 0.117
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Week 2	-0.04 10^9 cells/L Standard Deviation 0.126	0.01 10^9 cells/L Standard Deviation 0.074
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Week 4	0.00 10^9 cells/L Standard Deviation 0.115	0.01 10^9 cells/L Standard Deviation 0.057
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Week 8	0.04 10^9 cells/L Standard Deviation 0.052	0.07 10^9 cells/L Standard Deviation 0.125
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Week 12	-0.06 10^9 cells/L Standard Deviation 0.107	0.09 10^9 cells/L Standard Deviation 0.060
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Week 18	-0.02 10^9 cells/L Standard Deviation 0.092	0.08 10^9 cells/L Standard Deviation 0.109
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Week 24	-0.02 10^9 cells/L Standard Deviation 0.079	0.04 10^9 cells/L Standard Deviation 0.053
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Monocytes, Week 26	-0.03 10^9 cells/L Standard Deviation 0.116	0.07 10^9 cells/L Standard Deviation 0.100
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Day 2	0.12 10^9 cells/L Standard Deviation 1.497	0.05 10^9 cells/L Standard Deviation 0.693
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Day 3	-0.45 10^9 cells/L Standard Deviation 0.992	0.08 10^9 cells/L Standard Deviation 0.960
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Day 5	-0.15 10^9 cells/L Standard Deviation 0.941	0.08 10^9 cells/L Standard Deviation 1.090
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Week 1	-0.52 10^9 cells/L Standard Deviation 1.052	-0.21 10^9 cells/L Standard Deviation 1.179
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Week 2	0.19 10^9 cells/L Standard Deviation 1.819	-0.12 10^9 cells/L Standard Deviation 0.878
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Week 4	-0.42 10^9 cells/L Standard Deviation 1.096	-0.01 10^9 cells/L Standard Deviation 0.679
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Week 8	-0.16 10^9 cells/L Standard Deviation 1.178	-0.09 10^9 cells/L Standard Deviation 1.175
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Week 12	-0.48 10^9 cells/L Standard Deviation 1.212	0.19 10^9 cells/L Standard Deviation 0.483
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Week 18	-0.39 10^9 cells/L Standard Deviation 1.112	0.79 10^9 cells/L Standard Deviation 0.770
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Week 24	-0.06 10^9 cells/L Standard Deviation 0.999	0.33 10^9 cells/L Standard Deviation 0.819
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Neutrophils, Week 26	-0.13 10^9 cells/L Standard Deviation 1.591	0.77 10^9 cells/L Standard Deviation 1.052
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Day 2	-10.8 10^9 cells/L Standard Deviation 12.56	5.7 10^9 cells/L Standard Deviation 12.81
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Day 3	-1.9 10^9 cells/L Standard Deviation 14.16	-0.3 10^9 cells/L Standard Deviation 13.75
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Day 5	-6.1 10^9 cells/L Standard Deviation 10.18	1.7 10^9 cells/L Standard Deviation 15.90
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Week 1	-21.8 10^9 cells/L Standard Deviation 14.17	-5.5 10^9 cells/L Standard Deviation 11.71
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Week 2	-9.4 10^9 cells/L Standard Deviation 19.97	4.5 10^9 cells/L Standard Deviation 15.50
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Week 4	-10.4 10^9 cells/L Standard Deviation 15.77	7.5 10^9 cells/L Standard Deviation 19.55
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Week 8	-13.6 10^9 cells/L Standard Deviation 23.77	3.4 10^9 cells/L Standard Deviation 23.24
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Week 12	-15.6 10^9 cells/L Standard Deviation 23.68	4.3 10^9 cells/L Standard Deviation 47.56
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Week 18	-11.2 10^9 cells/L Standard Deviation 20.43	-1.7 10^9 cells/L Standard Deviation 29.48
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Week 24	-22.7 10^9 cells/L Standard Deviation 19.45	22.6 10^9 cells/L Standard Deviation 18.77
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Platelets, Week 26	-18.9 10^9 cells/L Standard Deviation 22.26	-2.7 10^9 cells/L Standard Deviation 25.31
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Day 2	-0.240 10^9 cells/L Standard Deviation 1.5414	-0.070 10^9 cells/L Standard Deviation 0.7424
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Day 3	-0.900 10^9 cells/L Standard Deviation 0.9752	-0.100 10^9 cells/L Standard Deviation 0.9404
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Day 5	-0.390 10^9 cells/L Standard Deviation 0.8465	-0.080 10^9 cells/L Standard Deviation 1.1203
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Week 1	-0.880 10^9 cells/L Standard Deviation 1.2506	-0.480 10^9 cells/L Standard Deviation 1.1203
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Week 2	-0.020 10^9 cells/L Standard Deviation 1.7061	-0.140 10^9 cells/L Standard Deviation 1.0035
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Week 4	-0.400 10^9 cells/L Standard Deviation 1.4314	-0.180 10^9 cells/L Standard Deviation 0.7899
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Week 8	-0.090 10^9 cells/L Standard Deviation 1.0546	-0.080 10^9 cells/L Standard Deviation 1.4382
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Week 12	-0.870 10^9 cells/L Standard Deviation 1.3073	0.111 10^9 cells/L Standard Deviation 0.5883
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Week 18	-0.640 10^9 cells/L Standard Deviation 1.1197	0.667 10^9 cells/L Standard Deviation 0.7778
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Week 24	-0.400 10^9 cells/L Standard Deviation 1.1025	0.034 10^9 cells/L Standard Deviation 0.8914
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes Leukocytes, Week 26	-0.470 10^9 cells/L Standard Deviation 1.4476	0.048 10^9 cells/L Standard Deviation 1.6991

SECONDARY outcome

Timeframe: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26

Blood samples were collected for the assessment of change from baseline in hematology parameters including Hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Hematology Parameter: Hemoglobin Week 4	-2.5 Gram per Liter Standard Deviation 7.88	-5.8 Gram per Liter Standard Deviation 7.19
Change From Baseline in Hematology Parameter: Hemoglobin Day 2	-3.5 Gram per Liter Standard Deviation 7.68	-2.1 Gram per Liter Standard Deviation 2.81
Change From Baseline in Hematology Parameter: Hemoglobin Day 3	-1.0 Gram per Liter Standard Deviation 6.25	-5.2 Gram per Liter Standard Deviation 4.85
Change From Baseline in Hematology Parameter: Hemoglobin Day 5	-3.6 Gram per Liter Standard Deviation 10.86	-6.2 Gram per Liter Standard Deviation 5.63
Change From Baseline in Hematology Parameter: Hemoglobin Week 1	-6.4 Gram per Liter Standard Deviation 10.94	-7.0 Gram per Liter Standard Deviation 5.64
Change From Baseline in Hematology Parameter: Hemoglobin Week 2	-2.5 Gram per Liter Standard Deviation 7.88	-7.5 Gram per Liter Standard Deviation 6.35
Change From Baseline in Hematology Parameter: Hemoglobin Week 8	-0.7 Gram per Liter Standard Deviation 9.27	-8.9 Gram per Liter Standard Deviation 4.79
Change From Baseline in Hematology Parameter: Hemoglobin Week 12	-2.2 Gram per Liter Standard Deviation 8.30	-8.9 Gram per Liter Standard Deviation 8.77
Change From Baseline in Hematology Parameter: Hemoglobin Week 18	-2.3 Gram per Liter Standard Deviation 8.83	-4.0 Gram per Liter Standard Deviation 6.12
Change From Baseline in Hematology Parameter: Hemoglobin Week 24	-4.3 Gram per Liter Standard Deviation 8.59	-5.4 Gram per Liter Standard Deviation 5.66
Change From Baseline in Hematology Parameter: Hemoglobin Week 26	-4.3 Gram per Liter Standard Deviation 6.63	-2.6 Gram per Liter Standard Deviation 7.49

SECONDARY outcome

Timeframe: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26

Blood samples were collected for the assessment of change from baseline in hematology parameters including Hematocrit. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Hematology Parameter: Hematocrit Day 2	-0.0112 Liter/liter Standard Deviation 0.0148	-0.0191 Liter/liter Standard Deviation 0.0105
Change From Baseline in Hematology Parameter: Hematocrit Day 3	-0.0077 Liter/liter Standard Deviation 0.0195	-0.0231 Liter/liter Standard Deviation 0.0197
Change From Baseline in Hematology Parameter: Hematocrit Day 5	-0.0136 Liter/liter Standard Deviation 0.0311	-0.0170 Liter/liter Standard Deviation 0.0180
Change From Baseline in Hematology Parameter: Hematocrit Week 1	-0.0189 Liter/liter Standard Deviation 0.0327	-0.0194 Liter/liter Standard Deviation 0.0170
Change From Baseline in Hematology Parameter: Hematocrit Week 2	-0.0075 Liter/liter Standard Deviation 0.0202	-0.0210 Liter/liter Standard Deviation 0.0173
Change From Baseline in Hematology Parameter: Hematocrit Week 4	-0.0092 Liter/liter Standard Deviation 0.0202	-0.0174 Liter/liter Standard Deviation 0.0181
Change From Baseline in Hematology Parameter: Hematocrit Week 8	0.0029 Liter/liter Standard Deviation 0.0248	-0.0210 Liter/liter Standard Deviation 0.0163
Change From Baseline in Hematology Parameter: Hematocrit Week 12	-0.0032 Liter/liter Standard Deviation 0.0232	-0.0241 Liter/liter Standard Deviation 0.0221
Change From Baseline in Hematology Parameter: Hematocrit Week 18	-0.0093 Liter/liter Standard Deviation 0.0234	-0.0084 Liter/liter Standard Deviation 0.0161
Change From Baseline in Hematology Parameter: Hematocrit Week 24	0.0003 Liter/liter Standard Deviation 0.0252	-0.0149 Liter/liter Standard Deviation 0.0099
Change From Baseline in Hematology Parameter: Hematocrit Week 26	-0.0021 Liter/liter Standard Deviation 0.0164	-0.0158 Liter/liter Standard Deviation 0.0169

SECONDARY outcome

Timeframe: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26

Blood samples were collected for the assessment of change from baseline in hematology parameters including mean corpuscular volume. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Day 2	-0.75 Femtoliters Standard Deviation 0.746	-0.23 Femtoliters Standard Deviation 0.403
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Day 3	1.41 Femtoliters Standard Deviation 1.457	0.60 Femtoliters Standard Deviation 0.400
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Day 5	-0.22 Femtoliters Standard Deviation 0.773	0.26 Femtoliters Standard Deviation 0.493
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Week 1	-0.46 Femtoliters Standard Deviation 0.769	0.09 Femtoliters Standard Deviation 0.318
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Week 2	-0.07 Femtoliters Standard Deviation 0.607	0.17 Femtoliters Standard Deviation 0.760
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Week 4	0.07 Femtoliters Standard Deviation 1.002	0.53 Femtoliters Standard Deviation 0.898
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Week 8	0.33 Femtoliters Standard Deviation 1.124	0.77 Femtoliters Standard Deviation 1.087
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Week 12	-0.27 Femtoliters Standard Deviation 1.427	-0.10 Femtoliters Standard Deviation 2.062
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Week 18	-0.13 Femtoliters Standard Deviation 1.425	0.27 Femtoliters Standard Deviation 1.885
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Week 24	0.50 Femtoliters Standard Deviation 0.627	0.56 Femtoliters Standard Deviation 1.544
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) Week 26	0.37 Femtoliters Standard Deviation 0.974	-0.96 Femtoliters Standard Deviation 1.726

SECONDARY outcome

Timeframe: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26

Blood samples were collected for the assessment of change from baseline in hematology parameters including mean Corpuscular Hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Day 2	-0.01 Picograms (pg) Standard Deviation 0.166	0.81 Picograms (pg) Standard Deviation 0.360
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Day 3	0.86 Picograms (pg) Standard Deviation 0.438	0.72 Picograms (pg) Standard Deviation 0.592
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Day 5	0.20 Picograms (pg) Standard Deviation 0.462	-0.04 Picograms (pg) Standard Deviation 0.267
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Week 1	-0.13 Picograms (pg) Standard Deviation 0.206	-0.04 Picograms (pg) Standard Deviation 0.313
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Week 2	-0.16 Picograms (pg) Standard Deviation 0.255	0.04 Picograms (pg) Standard Deviation 0.558
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Week 4	0.13 Picograms (pg) Standard Deviation 0.432	0.18 Picograms (pg) Standard Deviation 0.416
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Week 8	-0.18 Picograms (pg) Standard Deviation 0.266	-0.09 Picograms (pg) Standard Deviation 0.702
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Week 12	-0.33 Picograms (pg) Standard Deviation 0.374	-0.21 Picograms (pg) Standard Deviation 0.395
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Week 18	0.17 Picograms (pg) Standard Deviation 0.241	-0.11 Picograms (pg) Standard Deviation 0.504
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Week 24	-0.69 Picograms (pg) Standard Deviation 0.273	0.07 Picograms (pg) Standard Deviation 0.579
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) Week 26	-0.55 Picograms (pg) Standard Deviation 0.350	0.24 Picograms (pg) Standard Deviation 0.754

SECONDARY outcome

Timeframe: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26

Blood samples were collected for the assessment of change from baseline in hematology parameters including Reticulocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Hematology Parameter: Reticulocytes Day 5	0.083 Percentage Standard Deviation 0.2090	0.046 Percentage Standard Deviation 0.1254
Change From Baseline in Hematology Parameter: Reticulocytes Day 2	-0.052 Percentage Standard Deviation 0.1471	0.085 Percentage Standard Deviation 0.0669
Change From Baseline in Hematology Parameter: Reticulocytes Day 3	0.601 Percentage Standard Deviation 0.6413	0.162 Percentage Standard Deviation 0.0933
Change From Baseline in Hematology Parameter: Reticulocytes Week 1	0.004 Percentage Standard Deviation 0.1593	0.071 Percentage Standard Deviation 0.1091
Change From Baseline in Hematology Parameter: Reticulocytes Week 2	-0.047 Percentage Standard Deviation 0.1636	0.118 Percentage Standard Deviation 0.1686
Change From Baseline in Hematology Parameter: Reticulocytes Week 4	0.123 Percentage Standard Deviation 0.4205	0.134 Percentage Standard Deviation 0.1686
Change From Baseline in Hematology Parameter: Reticulocytes Week 8	0.107 Percentage Standard Deviation 0.3578	0.682 Percentage Standard Deviation 0.4978
Change From Baseline in Hematology Parameter: Reticulocytes Week 12	0.137 Percentage Standard Deviation 0.1762	0.656 Percentage Standard Deviation 0.2779
Change From Baseline in Hematology Parameter: Reticulocytes Week 18	0.037 Percentage Standard Deviation 0.2155	0.312 Percentage Standard Deviation 0.1923
Change From Baseline in Hematology Parameter: Reticulocytes Week 24	0.126 Percentage Standard Deviation 0.1675	0.624 Percentage Standard Deviation 0.3206
Change From Baseline in Hematology Parameter: Reticulocytes Week 26	0.099 Percentage Standard Deviation 0.1200	0.318 Percentage Standard Deviation 0.2828

SECONDARY outcome

Timeframe: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26

Change from baseline in hematology parameter including Erythrocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline In Hematology Parameter: Erythrocytes Day 2	-0.083 10^12 cells per liter Standard Deviation 0.1904	-0.197 10^12 cells per liter Standard Deviation 0.1225
Change From Baseline In Hematology Parameter: Erythrocytes Day 3	-0.160 10^12 cells per liter Standard Deviation 0.2322	-0.289 10^12 cells per liter Standard Deviation 0.2102
Change From Baseline In Hematology Parameter: Erythrocytes Day 5	-0.138 10^12 cells per liter Standard Deviation 0.3643	-0.205 10^12 cells per liter Standard Deviation 0.2059
Change From Baseline In Hematology Parameter: Erythrocytes Week 2	-0.080 10^12 cells per liter Standard Deviation 0.2262	-0.242 10^12 cells per liter Standard Deviation 0.2060
Change From Baseline In Hematology Parameter: Erythrocytes Week 4	-0.104 10^12 cells per liter Standard Deviation 0.1979	-0.225 10^12 cells per liter Standard Deviation 0.2154
Change From Baseline In Hematology Parameter: Erythrocytes Week 8	0.011 10^12 cells per liter Standard Deviation 0.2986	-0.271 10^12 cells per liter Standard Deviation 0.1777
Change From Baseline In Hematology Parameter: Erythrocytes Week 12	-0.019 10^12 cells per liter Standard Deviation 0.2729	-0.258 10^12 cells per liter Standard Deviation 0.2909
Change From Baseline In Hematology Parameter: Erythrocytes Week 1	-0.182 10^12 cells per liter Standard Deviation 0.3466	-0.221 10^12 cells per liter Standard Deviation 0.1875
Change From Baseline In Hematology Parameter: Erythrocytes Week 18	-0.097 10^12 cells per liter Standard Deviation 0.2589	-0.107 10^12 cells per liter Standard Deviation 0.2389
Change From Baseline In Hematology Parameter: Erythrocytes Week 24	-0.026 10^12 cells per liter Standard Deviation 0.2611	-0.189 10^12 cells per liter Standard Deviation 0.1619
Change From Baseline In Hematology Parameter: Erythrocytes Week 26	-0.043 10^12 cells per liter Standard Deviation 0.1945	-0.123 10^12 cells per liter Standard Deviation 0.2421

SECONDARY outcome

Timeframe: Baseline (Pre-dose on Day -1), Week 1, 4, 8, 12, 24 and Week 26

Blood samples was collected for the assessment of clinical chemistry parameters including Sodium, potassium, calcium, glucose, and urea. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26

Blood samples was collected for the assessment of clinical chemistry parameters including direct bilirubin, bilirubin, and creatinine\[MB10.1\]. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26

Blood samples was collected for the assessment of clinical chemistry parameters including AST, ALT, ALP, and GGT. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALP, Week 4	0.7 Units Per Liter Standard Deviation 7.17	1.3 Units Per Liter Standard Deviation 6.75
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALP, Week 1	-1.7 Units Per Liter Standard Deviation 4.92	-1.9 Units Per Liter Standard Deviation 6.94
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALP, Week 8	0.9 Units Per Liter Standard Deviation 7.23	-2.7 Units Per Liter Standard Deviation 4.06
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALP, Week 12	1.5 Units Per Liter Standard Deviation 6.88	-3.4 Units Per Liter Standard Deviation 6.44
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALP, Week 24	3.9 Units Per Liter Standard Deviation 9.34	-0.9 Units Per Liter Standard Deviation 9.10
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALP, Week 26	1.2 Units Per Liter Standard Deviation 6.99	1.6 Units Per Liter Standard Deviation 7.91
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALT, Week 1	1.0 Units Per Liter Standard Deviation 6.70	-3.4 Units Per Liter Standard Deviation 3.89
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALT, Week 4	-0.7 Units Per Liter Standard Deviation 4.32	-2.8 Units Per Liter Standard Deviation 8.00
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALT, Week 8	1.9 Units Per Liter Standard Deviation 6.67	-0.8 Units Per Liter Standard Deviation 8.80
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALT, Week 12	3.6 Units Per Liter Standard Deviation 6.70	-1.9 Units Per Liter Standard Deviation 9.97
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALT, Week 24	3.3 Units Per Liter Standard Deviation 9.24	-3.1 Units Per Liter Standard Deviation 8.98
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) ALT, Week 26	0.6 Units Per Liter Standard Deviation 6.59	0.9 Units Per Liter Standard Deviation 18.18
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) AST, Week 1	1.5 Units Per Liter Standard Deviation 2.01	-0.6 Units Per Liter Standard Deviation 5.13
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) AST, Week 4	1.6 Units Per Liter Standard Deviation 3.72	0.6 Units Per Liter Standard Deviation 6.69
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) AST, Week 8	1.3 Units Per Liter Standard Deviation 3.56	-0.2 Units Per Liter Standard Deviation 2.86
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) AST, Week 12	3.1 Units Per Liter Standard Deviation 4.04	2.1 Units Per Liter Standard Deviation 4.88
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) AST, Week 24	2.9 Units Per Liter Standard Deviation 4.15	0.2 Units Per Liter Standard Deviation 2.91
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) AST, Week 26	1.1 Units Per Liter Standard Deviation 3.48	4.8 Units Per Liter Standard Deviation 7.64
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) GGT, Week 1	0.8 Units Per Liter Standard Deviation 2.94	-0.5 Units Per Liter Standard Deviation 2.99
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) GGT, Week 4	0.1 Units Per Liter Standard Deviation 2.23	-0.2 Units Per Liter Standard Deviation 4.24
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) GGT, Week 8	5.6 Units Per Liter Standard Deviation 5.97	4.1 Units Per Liter Standard Deviation 14.50
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) GGT, Week 12	4.2 Units Per Liter Standard Deviation 3.19	-0.4 Units Per Liter Standard Deviation 5.70
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) GGT, Week 24	5.1 Units Per Liter Standard Deviation 7.82	-0.1 Units Per Liter Standard Deviation 6.11
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) GGT, Week 26	4.5 Units Per Liter Standard Deviation 4.70	0.1 Units Per Liter Standard Deviation 7.25

SECONDARY outcome

Timeframe: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26

Blood samples was collected for the assessment of clinical chemistry parameters including Albumin. and Total Protein. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Albumin, Week 1	-1.13 Grams per Liter Standard Deviation 1.973	-1.62 Grams per Liter Standard Deviation 1.266
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Albumin, Week 4	-0.89 Grams per Liter Standard Deviation 2.529	-0.83 Grams per Liter Standard Deviation 1.641
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Albumin, Week 8	-0.03 Grams per Liter Standard Deviation 1.983	-0.57 Grams per Liter Standard Deviation 2.434
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Albumin, Week 12	-0.73 Grams per Liter Standard Deviation 1.800	-0.56 Grams per Liter Standard Deviation 1.965
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Albumin, Week 24	-2.12 Grams per Liter Standard Deviation 2.198	0.20 Grams per Liter Standard Deviation 1.356
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Albumin, Week 26	-1.59 Grams per Liter Standard Deviation 2.366	-0.24 Grams per Liter Standard Deviation 1.775
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Total Protein, Week 1	-2.49 Grams per Liter Standard Deviation 3.504	-2.02 Grams per Liter Standard Deviation 2.147
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Total Protein, Week 4	-3.61 Grams per Liter Standard Deviation 4.100	-1.60 Grams per Liter Standard Deviation 2.659
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Total Protein, Week 8	-2.67 Grams per Liter Standard Deviation 3.492	-1.80 Grams per Liter Standard Deviation 3.629
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Total Protein, Week 12	-2.44 Grams per Liter Standard Deviation 2.274	-2.02 Grams per Liter Standard Deviation 3.337
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Total Protein, Week 24	-3.22 Grams per Liter Standard Deviation 3.858	-1.71 Grams per Liter Standard Deviation 2.461
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein Total Protein, Week 26	-2.38 Grams per Liter Standard Deviation 3.379	-2.86 Grams per Liter Standard Deviation 2.511

SECONDARY outcome

Timeframe: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26

Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C3, Week 1	0.836 Grams per Liter Interval 0.745 to 0.939	0.899 Grams per Liter Interval 0.798 to 1.012
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C3, Week 4	0.867 Grams per Liter Interval 0.788 to 0.954	0.840 Grams per Liter Interval 0.741 to 0.952
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C3, Week 8	0.888 Grams per Liter Interval 0.796 to 0.99	0.896 Grams per Liter Interval 0.765 to 1.051
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C3, Week 12	0.852 Grams per Liter Interval 0.755 to 0.961	0.888 Grams per Liter Interval 0.772 to 1.023
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C3, Week 24	0.845 Grams per Liter Interval 0.754 to 0.948	0.912 Grams per Liter Interval 0.782 to 1.064
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C3, Week 26	0.883 Grams per Liter Interval 0.781 to 0.998	0.886 Grams per Liter Interval 0.784 to 1.002
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C4, Baseline	0.211 Grams per Liter Interval 0.175 to 0.254	0.197 Grams per Liter Interval 0.175 to 0.223
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C4, Week 1	0.205 Grams per Liter Interval 0.173 to 0.242	0.200 Grams per Liter Interval 0.175 to 0.228
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C4, Week 4	0.202 Grams per Liter Interval 0.17 to 0.241	0.183 Grams per Liter Interval 0.156 to 0.214
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C4, Week 8	0.201 Grams per Liter Interval 0.172 to 0.234	0.202 Grams per Liter Interval 0.174 to 0.235
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C4, Week 12	0.194 Grams per Liter Interval 0.163 to 0.231	0.213 Grams per Liter Interval 0.172 to 0.263
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C4, Week 24	0.205 Grams per Liter Interval 0.174 to 0.242	0.200 Grams per Liter Interval 0.168 to 0.238
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C4, Week 26	0.219 Grams per Liter Interval 0.184 to 0.261	0.205 Grams per Liter Interval 0.178 to 0.235
Absolute Values of Complement C3 And C4 at Each Timepoint Complement C3, Baseline	0.876 Grams per Liter Interval 0.78 to 0.985	0.913 Grams per Liter Interval 0.798 to 1.046

SECONDARY outcome

Timeframe: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26

Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C3, Week 1 Ratio to Baseline	0.954 Ratio Interval 0.889 to 1.024	0.984 Ratio Interval 0.915 to 1.059
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C3, Week 4, Ratio to Baseline	0.989 Ratio Interval 0.945 to 1.036	0.919 Ratio Interval 0.83 to 1.019
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C3, Week 12, Ratio to Baseline	0.972 Ratio Interval 0.907 to 1.042	1.002 Ratio Interval 0.913 to 1.1
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C3, Week 8, Ratio to Baseline	1.013 Ratio Interval 0.935 to 1.098	0.981 Ratio Interval 0.865 to 1.114
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C3, Week 24, Ratio to Baseline	0.965 Ratio Interval 0.876 to 1.062	1.028 Ratio Interval 0.976 to 1.084
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C3, Week 26, Ratio to Baseline	1.008 Ratio Interval 0.934 to 1.087	0.999 Ratio Interval 0.92 to 1.085
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C4, Week 1, Ratio to Baseline	0.972 Ratio Interval 0.863 to 1.095	1.013 Ratio Interval 0.895 to 1.146
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C4, Week 4, Ratio to Baseline	0.959 Ratio Interval 0.821 to 1.119	0.926 Ratio Interval 0.813 to 1.056
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C4, Week 8, Ratio to Baseline	0.952 Ratio Interval 0.85 to 1.067	1.024 Ratio Interval 0.858 to 1.222
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C4, Week 12, Ratio to Baseline	0.919 Ratio Interval 0.813 to 1.04	1.101 Ratio Interval 0.972 to 1.246
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C4, Week 24, Ratio to Baseline	0.973 Ratio Interval 0.873 to 1.085	1.034 Ratio Interval 0.952 to 1.122
Ratio to Baseline at Each Timepoint of Complement C3 And C4 Complement C4, Week 26, Ratio to Baseline	1.040 Ratio Interval 0.925 to 1.168	1.060 Ratio Interval 0.989 to 1.135

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 1 (2 hours), Day 1 (8 hours), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26

Systolic blood pressure (sBP) is a measure of blood pressure while the heart is beating. Diastolic blood pressure (dBP) is a measure of blood pressure while the heart is relaxed. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 1 (2 hours), Day 1 (8 hours), Day 2, 3, 5, Week 1, 2, 4, 8, 12, 18, 24 and 26

Body temperature was measured in participants in resting state. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Body Temperature Week 2	0.01 Degrees Celsius Standard Deviation 0.303	0.20 Degrees Celsius Standard Deviation 0.380
Change From Baseline in Body Temperature Week 4	-0.18 Degrees Celsius Standard Deviation 0.336	-0.09 Degrees Celsius Standard Deviation 0.335
Change From Baseline in Body Temperature Day 3	-0.10 Degrees Celsius Standard Deviation 0.353	0.11 Degrees Celsius Standard Deviation 0.247
Change From Baseline in Body Temperature Day 5	-0.05 Degrees Celsius Standard Deviation 0.341	0.45 Degrees Celsius Standard Deviation 0.381
Change From Baseline in Body Temperature Week 1	-0.25 Degrees Celsius Standard Deviation 0.360	0.16 Degrees Celsius Standard Deviation 0.295
Change From Baseline in Body Temperature Week 8	-0.14 Degrees Celsius Standard Deviation 0.212	0.28 Degrees Celsius Standard Deviation 0.286
Change From Baseline in Body Temperature Week 12	-0.05 Degrees Celsius Standard Deviation 0.331	0.29 Degrees Celsius Standard Deviation 0.330
Change From Baseline in Body Temperature Week 18	-0.04 Degrees Celsius Standard Deviation 0.347	0.11 Degrees Celsius Standard Deviation 0.314
Change From Baseline in Body Temperature Week 24	0.01 Degrees Celsius Standard Deviation 0.285	0.11 Degrees Celsius Standard Deviation 0.440
Change From Baseline in Body Temperature Week 26	0.20 Degrees Celsius Standard Deviation 0.316	0.37 Degrees Celsius Standard Deviation 0.421
Change From Baseline in Body Temperature Day 1, 2 hours	0.07 Degrees Celsius Standard Deviation 0.291	0.19 Degrees Celsius Standard Deviation 0.328
Change From Baseline in Body Temperature Day 1, 8 hours	0.21 Degrees Celsius Standard Deviation 0.152	0.44 Degrees Celsius Standard Deviation 0.284
Change From Baseline in Body Temperature Day 2	-0.05 Degrees Celsius Standard Deviation 0.259	0.12 Degrees Celsius Standard Deviation 0.339

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 1 (2 hour), Day 1 (8 hour), Day 2, 3, 5, Week 1, 4, 8, 12, 18, 24 and Week 26

The vital signs followed in this analysis was pulse rate, expressed as beats per minute (bpm). Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Pulse Rate Pulse Rate, Week 12	0.54 Beats per minute (BPM) Standard Deviation 12.479	6.62 Beats per minute (BPM) Standard Deviation 11.918
Change From Baseline in Pulse Rate Pulse Rate, Week 18	3.04 Beats per minute (BPM) Standard Deviation 15.689	11.73 Beats per minute (BPM) Standard Deviation 12.640
Change From Baseline in Pulse Rate Pulse Rate, Day 1, 2 hour	-5.96 Beats per minute (BPM) Standard Deviation 5.529	2.13 Beats per minute (BPM) Standard Deviation 6.755
Change From Baseline in Pulse Rate Pulse Rate, Day 1, 8 hour	-4.16 Beats per minute (BPM) Standard Deviation 5.999	1.63 Beats per minute (BPM) Standard Deviation 5.892
Change From Baseline in Pulse Rate Pulse Rate, Day 2	7.24 Beats per minute (BPM) Standard Deviation 7.626	9.53 Beats per minute (BPM) Standard Deviation 8.596
Change From Baseline in Pulse Rate Pulse Rate, Day 3	1.14 Beats per minute (BPM) Standard Deviation 9.195	4.53 Beats per minute (BPM) Standard Deviation 9.833
Change From Baseline in Pulse Rate Pulse Rate, Day 5	4.74 Beats per minute (BPM) Standard Deviation 13.378	6.83 Beats per minute (BPM) Standard Deviation 8.631
Change From Baseline in Pulse Rate Pulse Rate, Week 1	0.94 Beats per minute (BPM) Standard Deviation 9.393	5.73 Beats per minute (BPM) Standard Deviation 6.001
Change From Baseline in Pulse Rate Pulse Rate, Week 2	5.24 Beats per minute (BPM) Standard Deviation 9.965	8.53 Beats per minute (BPM) Standard Deviation 5.714
Change From Baseline in Pulse Rate Pulse Rate, Week 4	2.24 Beats per minute (BPM) Standard Deviation 10.036	7.73 Beats per minute (BPM) Standard Deviation 10.994
Change From Baseline in Pulse Rate Pulse Rate, Week 8	1.24 Beats per minute (BPM) Standard Deviation 9.359	5.13 Beats per minute (BPM) Standard Deviation 8.495
Change From Baseline in Pulse Rate Pulse Rate, Week 24	-0.06 Beats per minute (BPM) Standard Deviation 13.603	14.73 Beats per minute (BPM) Standard Deviation 9.943
Change From Baseline in Pulse Rate Pulse Rate, Week 26	3.74 Beats per minute (BPM) Standard Deviation 15.365	14.73 Beats per minute (BPM) Standard Deviation 11.377

SECONDARY outcome

Timeframe: Baseline (Day -1), Day 1 (2 hour), Day 1 (8 hour), Day 2, 3, 5, Week 1, 4, 8, 12, 18, 24 and Week 26

12-lead ECG were performed in a supine position using an automated ECG machine that calculated the heart rate and measured PR interval, QRS duration, QT interval and corrected QT using Fridericia's Formula (QTc\[MB13.1\]F) intervals. ECG measurements were performed in triplicate. When multiple ECGs were performed at the same planned timepoint, the aggregate \[MB14.1\]value of each parameter was used. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Day 1, 2 hour	-0.84 Milliseconds Standard Deviation 4.344	-2.64 Milliseconds Standard Deviation 12.942
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Day 1, 8 hour	-2.27 Milliseconds Standard Deviation 3.900	-3.65 Milliseconds Standard Deviation 11.480
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Day 2	4.53 Milliseconds Standard Deviation 12.204	-0.46 Milliseconds Standard Deviation 13.476
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Day 3	-0.20 Milliseconds Standard Deviation 8.295	0.23 Milliseconds Standard Deviation 9.007
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Day 5	1.33 Milliseconds Standard Deviation 7.378	-3.38 Milliseconds Standard Deviation 12.322
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Week 1	1.08 Milliseconds Standard Deviation 8.925	-0.92 Milliseconds Standard Deviation 11.653
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Week 2	4.04 Milliseconds Standard Deviation 16.780	0.07 Milliseconds Standard Deviation 9.145
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Week 4	5.45 Milliseconds Standard Deviation 11.707	2.43 Milliseconds Standard Deviation 12.669
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Week 8	3.46 Milliseconds Standard Deviation 5.707	0.83 Milliseconds Standard Deviation 11.991
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Week 12	2.53 Milliseconds Standard Deviation 4.195	-1.60 Milliseconds Standard Deviation 15.803
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Week 18	1.78 Milliseconds Standard Deviation 3.036	-1.32 Milliseconds Standard Deviation 11.759
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Week 24	2.13 Milliseconds Standard Deviation 3.876	-0.36 Milliseconds Standard Deviation 15.513
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate PR Interval, Aggregate, Week 26	4.40 Milliseconds Standard Deviation 7.092	-2.89 Milliseconds Standard Deviation 11.269
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Day 1, 2 hour	-1.63 Milliseconds Standard Deviation 1.493	-0.82 Milliseconds Standard Deviation 2.483
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Day 1, 8 hour	-0.48 Milliseconds Standard Deviation 1.954	-1.26 Milliseconds Standard Deviation 1.973
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Day 2	0.39 Milliseconds Standard Deviation 2.023	0.00 Milliseconds Standard Deviation 2.253
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Day 3	1.89 Milliseconds Standard Deviation 2.821	0.41 Milliseconds Standard Deviation 1.902
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Day 5	-0.36 Milliseconds Standard Deviation 2.627	-0.34 Milliseconds Standard Deviation 3.247
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Week 1	0.03 Milliseconds Standard Deviation 1.737	-2.27 Milliseconds Standard Deviation 2.295
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Week 2	0.26 Milliseconds Standard Deviation 2.196	-0.93 Milliseconds Standard Deviation 1.937
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Week 4	0.15 Milliseconds Standard Deviation 3.106	-0.59 Milliseconds Standard Deviation 1.954
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Week 8	1.19 Milliseconds Standard Deviation 2.745	-0.80 Milliseconds Standard Deviation 2.106
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Week 12	0.93 Milliseconds Standard Deviation 3.296	-0.81 Milliseconds Standard Deviation 2.597
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Week 18	1.40 Milliseconds Standard Deviation 3.351	0.02 Milliseconds Standard Deviation 3.145
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Week 24	0.46 Milliseconds Standard Deviation 1.795	-2.14 Milliseconds Standard Deviation 2.546
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QRS Duration, Aggregate, Week 26	-0.41 Milliseconds Standard Deviation 3.316	-4.07 Milliseconds Standard Deviation 2.887
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Day 1, 2 hour	-5.21 Milliseconds Standard Deviation 5.651	-8.39 Milliseconds Standard Deviation 17.499
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Day 1, 8 hour	-1.39 Milliseconds Standard Deviation 8.188	-6.92 Milliseconds Standard Deviation 16.608
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Day 2	-18.21 Milliseconds Standard Deviation 8.801	-21.93 Milliseconds Standard Deviation 9.133
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Day 3	-16.94 Milliseconds Standard Deviation 14.136	-34.99 Milliseconds Standard Deviation 18.932
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Day 5	-20.66 Milliseconds Standard Deviation 16.160	-19.39 Milliseconds Standard Deviation 15.006
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Week 1	-4.01 Milliseconds Standard Deviation 12.293	-8.60 Milliseconds Standard Deviation 16.612
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Week 2	-15.61 Milliseconds Standard Deviation 17.242	-17.66 Milliseconds Standard Deviation 12.158
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Week 4	-11.01 Milliseconds Standard Deviation 14.937	-11.07 Milliseconds Standard Deviation 21.302
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Week 8	-10.34 Milliseconds Standard Deviation 14.871	-11.67 Milliseconds Standard Deviation 13.038
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Week 12	-7.13 Milliseconds Standard Deviation 18.140	-12.78 Milliseconds Standard Deviation 18.728
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Week 18	-4.47 Milliseconds Standard Deviation 22.321	-19.39 Milliseconds Standard Deviation 20.395
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Week 24	-6.01 Milliseconds Standard Deviation 26.007	-23.96 Milliseconds Standard Deviation 16.773
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QT Interval, Aggregate, Week 26	-7.27 Milliseconds Standard Deviation 22.688	-33.78 Milliseconds Standard Deviation 17.359
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Day 1, 2 hour	-12.59 Milliseconds Standard Deviation 3.511	-11.63 Milliseconds Standard Deviation 16.082
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Day 1, 8 hour	-6.20 Milliseconds Standard Deviation 6.892	-7.97 Milliseconds Standard Deviation 7.896
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Day 2	-5.97 Milliseconds Standard Deviation 6.321	-9.73 Milliseconds Standard Deviation 7.506
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Day 3	-10.09 Milliseconds Standard Deviation 6.675	-26.49 Milliseconds Standard Deviation 9.100
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Day 5	-7.04 Milliseconds Standard Deviation 8.360	-9.57 Milliseconds Standard Deviation 8.345
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Week 1	-2.82 Milliseconds Standard Deviation 6.837	-3.45 Milliseconds Standard Deviation 10.648
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Week 2	-4.94 Milliseconds Standard Deviation 6.690	-7.17 Milliseconds Standard Deviation 10.401
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Week 4	-2.34 Milliseconds Standard Deviation 5.754	-5.07 Milliseconds Standard Deviation 10.253
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Week 8	-2.91 Milliseconds Standard Deviation 7.425	-4.00 Milliseconds Standard Deviation 9.108
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Week 12	-1.84 Milliseconds Standard Deviation 4.347	-5.67 Milliseconds Standard Deviation 10.444
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Week 18	4.98 Milliseconds Standard Deviation 5.990	-2.93 Milliseconds Standard Deviation 10.040
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Week 24	0.62 Milliseconds Standard Deviation 8.127	-8.71 Milliseconds Standard Deviation 6.705
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate QTcF Interval, Aggregate, Week 26	-1.71 Milliseconds Standard Deviation 6.968	-11.20 Milliseconds Standard Deviation 10.311

SECONDARY outcome

Timeframe: Day 1 (Pre-dose), Week 4, Week 12, and Week 26

Serum samples were collected to determine the presence of anti-depemokimab binding antibodies using a validated bioanalytical method. Data is reported by visit. The results were categorized as negative and positive. A participant is considered positive if they have at least one positive post-Baseline ADA result. Number of participants with positive ADAs against depemokimab was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Depemokimab Day 1, Pre-dose	0 Participants	0 Participants
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Depemokimab Week 4	0 Participants	0 Participants
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Depemokimab Week 12	0 Participants	0 Participants
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Depemokimab Week 26	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Week 26

Population: The analysis was performed on the Safety Set that included all participants who received at least one dose of study intervention. Participants were analysed according to the intervention they actually received. No participants had positive ADAs to depemokimab therefore, no data was collected for titers of ADAs.

Serum samples were collected to determine the presence of anti-depemokimab binding antibodies using a validated bioanalytical method. Data is reported by visit. Titer was only measured when a positive result was found.

Outcome measures

Outcome data not reported

Adverse Events

Depemokimab 100mg

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

Depemokimab 300mg

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER

Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Urea, Week 26	0.179 Millimoles per liter Standard Deviation 0.9985	0.067 Millimoles per liter Standard Deviation 0.9667
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Glucose, Week 1	0.151 Millimoles per liter Standard Deviation 0.2426	-0.138 Millimoles per liter Standard Deviation 0.3356
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Glucose, Week 4	0.089 Millimoles per liter Standard Deviation 0.2552	0.327 Millimoles per liter Standard Deviation 1.2921
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Glucose, Week 8	0.030 Millimoles per liter Standard Deviation 0.3929	-0.026 Millimoles per liter Standard Deviation 0.3219
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Glucose, Week 12	0.151 Millimoles per liter Standard Deviation 0.2487	-0.132 Millimoles per liter Standard Deviation 0.3391
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Glucose, Week 24	-0.169 Millimoles per liter Standard Deviation 0.4133	0.468 Millimoles per liter Standard Deviation 0.3080
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Urea, Week 24	0.215 Millimoles per liter Standard Deviation 0.7788	0.318 Millimoles per liter Standard Deviation 0.5073
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Glucose, Week 26	-0.271 Millimoles per liter Standard Deviation 0.3511	0.350 Millimoles per liter Standard Deviation 0.6094
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Sodium, Week 1	1.1 Millimoles per liter Standard Deviation 1.10	0.9 Millimoles per liter Standard Deviation 1.73
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Sodium, Week 4	-0.3 Millimoles per liter Standard Deviation 1.57	0.1 Millimoles per liter Standard Deviation 1.91
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Sodium, Week 8	0.3 Millimoles per liter Standard Deviation 1.06	0.9 Millimoles per liter Standard Deviation 2.23
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Sodium, Week 12	-1.1 Millimoles per liter Standard Deviation 1.79	-0.1 Millimoles per liter Standard Deviation 2.09
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Sodium, Week 24	-1.7 Millimoles per liter Standard Deviation 2.50	0.7 Millimoles per liter Standard Deviation 2.29
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Sodium, Week 26	-0.9 Millimoles per liter Standard Deviation 1.60	0.1 Millimoles per liter Standard Deviation 1.83
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Potassium, Week 1	0.045 Millimoles per liter Standard Deviation 0.1932	-0.106 Millimoles per liter Standard Deviation 0.1246
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Potassium, Week 4	-0.031 Millimoles per liter Standard Deviation 0.2265	-0.189 Millimoles per liter Standard Deviation 0.2365
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Potassium, Week 8	-0.028 Millimoles per liter Standard Deviation 0.3262	-0.242 Millimoles per liter Standard Deviation 0.1728
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Potassium, Week 12	-0.042 Millimoles per liter Standard Deviation 0.2665	-0.427 Millimoles per liter Standard Deviation 0.2293
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Potassium, Week 24	-0.131 Millimoles per liter Standard Deviation 0.2347	-0.098 Millimoles per liter Standard Deviation 0.1161
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Potassium, Week 26	-0.106 Millimoles per liter Standard Deviation 0.2360	-0.252 Millimoles per liter Standard Deviation 0.1716
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Calcium, Week 1	0.052 Millimoles per liter Standard Deviation 0.1105	-0.037 Millimoles per liter Standard Deviation 0.0295
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Calcium, Week 4	0.010 Millimoles per liter Standard Deviation 0.1159	-0.002 Millimoles per liter Standard Deviation 0.0432
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Calcium, Week 8	0.065 Millimoles per liter Standard Deviation 0.1084	-0.018 Millimoles per liter Standard Deviation 0.1054
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Calcium, Week 12	0.039 Millimoles per liter Standard Deviation 0.1034	-0.017 Millimoles per liter Standard Deviation 0.0901
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Calcium, Week 24	0.073 Millimoles per liter Standard Deviation 0.1335	0.021 Millimoles per liter Standard Deviation 0.0326
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Calcium, Week 26	0.018 Millimoles per liter Standard Deviation 0.1036	-0.111 Millimoles per liter Standard Deviation 0.0824
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Urea, Week 1	0.447 Millimoles per liter Standard Deviation 1.1678	0.084 Millimoles per liter Standard Deviation 0.8962
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Urea, Week 4	0.083 Millimoles per liter Standard Deviation 0.6965	0.679 Millimoles per liter Standard Deviation 0.9138
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Urea, Week 8	0.251 Millimoles per liter Standard Deviation 0.8523	0.164 Millimoles per liter Standard Deviation 1.0094
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea Urea, Week 12	0.069 Millimoles per liter Standard Deviation 0.6141	0.102 Millimoles per liter Standard Deviation 0.6358

Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Direct Bilirubin, Week 1	-0.62 Micromoles per Liter Standard Deviation 1.262	0.17 Micromoles per Liter Standard Deviation 0.996
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Direct Bilirubin, Week 4	-0.30 Micromoles per Liter Standard Deviation 1.572	-0.28 Micromoles per Liter Standard Deviation 1.778
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Direct Bilirubin, Week 8	-0.77 Micromoles per Liter Standard Deviation 1.451	0.74 Micromoles per Liter Standard Deviation 1.059
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Direct Bilirubin, Week 12	0.12 Micromoles per Liter Standard Deviation 2.404	0.79 Micromoles per Liter Standard Deviation 0.862
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Direct Bilirubin, Week 24	-0.12 Micromoles per Liter Standard Deviation 1.497	0.27 Micromoles per Liter Standard Deviation 1.228
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Direct Bilirubin, Week 26	0.22 Micromoles per Liter Standard Deviation 2.140	0.61 Micromoles per Liter Standard Deviation 2.781
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Bilirubin, Week 1	-2.10 Micromoles per Liter Standard Deviation 3.544	0.14 Micromoles per Liter Standard Deviation 3.622
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Bilirubin, Week 4	-1.19 Micromoles per Liter Standard Deviation 5.297	-1.57 Micromoles per Liter Standard Deviation 6.771
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Bilirubin, Week 8	-1.27 Micromoles per Liter Standard Deviation 4.252	0.99 Micromoles per Liter Standard Deviation 2.915
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Bilirubin, Week 12	1.03 Micromoles per Liter Standard Deviation 6.365	0.48 Micromoles per Liter Standard Deviation 2.618
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Bilirubin, Week 24	-0.38 Micromoles per Liter Standard Deviation 4.361	-0.32 Micromoles per Liter Standard Deviation 4.346
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Bilirubin, Week 26	1.06 Micromoles per Liter Standard Deviation 5.719	-1.14 Micromoles per Liter Standard Deviation 8.219
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Creatinine, Week 1	-0.6 Micromoles per Liter Standard Deviation 7.46	-4.1 Micromoles per Liter Standard Deviation 4.09
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Creatinine, Week 4	0.7 Micromoles per Liter Standard Deviation 4.88	1.6 Micromoles per Liter Standard Deviation 6.19
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Creatinine, Week 8	2.5 Micromoles per Liter Standard Deviation 9.91	2.5 Micromoles per Liter Standard Deviation 6.72
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Creatinine, Week 12	0.1 Micromoles per Liter Standard Deviation 7.49	-2.1 Micromoles per Liter Standard Deviation 5.71
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Creatinine, Week 24	0.1 Micromoles per Liter Standard Deviation 5.63	-1.0 Micromoles per Liter Standard Deviation 7.19
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine Creatinine, Week 26	-1.5 Micromoles per Liter Standard Deviation 7.35	-0.3 Micromoles per Liter Standard Deviation 6.75

Measure	Depemokimab 100mg n=10 Participants Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.	Depemokimab 300mg n=10 Participants Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Day 1 (2 hours)	-4.48 Millimeters of mercury (mmHg) Standard Deviation 6.933	0.34 Millimeters of mercury (mmHg) Standard Deviation 6.963
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Day 1 (8 hours)	1.22 Millimeters of mercury (mmHg) Standard Deviation 6.522	2.54 Millimeters of mercury (mmHg) Standard Deviation 6.318
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Day 2	1.72 Millimeters of mercury (mmHg) Standard Deviation 6.086	1.34 Millimeters of mercury (mmHg) Standard Deviation 7.115
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Day 3	1.22 Millimeters of mercury (mmHg) Standard Deviation 7.632	2.64 Millimeters of mercury (mmHg) Standard Deviation 7.111
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Day 5	3.52 Millimeters of mercury (mmHg) Standard Deviation 8.877	2.24 Millimeters of mercury (mmHg) Standard Deviation 7.363
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Week 1	4.72 Millimeters of mercury (mmHg) Standard Deviation 7.952	-1.36 Millimeters of mercury (mmHg) Standard Deviation 6.679
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Week 2	1.92 Millimeters of mercury (mmHg) Standard Deviation 5.797	0.74 Millimeters of mercury (mmHg) Standard Deviation 3.063
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Week 4	0.02 Millimeters of mercury (mmHg) Standard Deviation 6.091	-0.06 Millimeters of mercury (mmHg) Standard Deviation 5.622
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Week 8	4.92 Millimeters of mercury (mmHg) Standard Deviation 5.034	-0.66 Millimeters of mercury (mmHg) Standard Deviation 6.173
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Week 12	-2.18 Millimeters of mercury (mmHg) Standard Deviation 7.916	0.08 Millimeters of mercury (mmHg) Standard Deviation 6.943
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Week 18	-1.18 Millimeters of mercury (mmHg) Standard Deviation 10.532	0.52 Millimeters of mercury (mmHg) Standard Deviation 6.905
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Week 24	-2.78 Millimeters of mercury (mmHg) Standard Deviation 5.849	4.52 Millimeters of mercury (mmHg) Standard Deviation 10.418
Change From Baseline in Systolic and Diastolic Blood Pressure sBP, Week 26	-4.88 Millimeters of mercury (mmHg) Standard Deviation 8.527	2.97 Millimeters of mercury (mmHg) Standard Deviation 8.819
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Day 1 (2 hours)	1.30 Millimeters of mercury (mmHg) Standard Deviation 7.002	-1.99 Millimeters of mercury (mmHg) Standard Deviation 7.861
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Day 1 (8 hours)	1.90 Millimeters of mercury (mmHg) Standard Deviation 5.045	0.11 Millimeters of mercury (mmHg) Standard Deviation 5.180
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Day 2	1.40 Millimeters of mercury (mmHg) Standard Deviation 3.960	-2.29 Millimeters of mercury (mmHg) Standard Deviation 5.842
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Day 3	1.60 Millimeters of mercury (mmHg) Standard Deviation 2.823	-3.09 Millimeters of mercury (mmHg) Standard Deviation 6.931
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Day 5	3.10 Millimeters of mercury (mmHg) Standard Deviation 6.056	-1.89 Millimeters of mercury (mmHg) Standard Deviation 6.662
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Week 1	4.90 Millimeters of mercury (mmHg) Standard Deviation 4.303	-3.39 Millimeters of mercury (mmHg) Standard Deviation 6.107
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Week 2	5.20 Millimeters of mercury (mmHg) Standard Deviation 4.454	-4.59 Millimeters of mercury (mmHg) Standard Deviation 4.786
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Week 4	4.50 Millimeters of mercury (mmHg) Standard Deviation 4.463	-2.59 Millimeters of mercury (mmHg) Standard Deviation 5.633
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Week 8	4.20 Millimeters of mercury (mmHg) Standard Deviation 6.244	-2.49 Millimeters of mercury (mmHg) Standard Deviation 6.243
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Week 12	3.20 Millimeters of mercury (mmHg) Standard Deviation 5.759	-1.96 Millimeters of mercury (mmHg) Standard Deviation 6.028
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Week 18	4.10 Millimeters of mercury (mmHg) Standard Deviation 4.078	-1.07 Millimeters of mercury (mmHg) Standard Deviation 6.905
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Week 24	3.50 Millimeters of mercury (mmHg) Standard Deviation 4.622	-1.73 Millimeters of mercury (mmHg) Standard Deviation 6.803
Change From Baseline in Systolic and Diastolic Blood Pressure dBP, Week 26	2.50 Millimeters of mercury (mmHg) Standard Deviation 4.602	0.93 Millimeters of mercury (mmHg) Standard Deviation 8.825